Boehringer Ingelheim Pharmaceuticals, Inc. Release: Dabigatran Etexilate (Pradaxa®) Associated with Significantly Lower Rates of Fatal and Traumatic Intracranial Haemorrhage Compared with Warfarin

INGELHEIM, Germany--(BUSINESS WIRE)--A new analysis of the 18,113 patient, RE-LY® trial highlights significantly lower rates of both fatal and traumatic intracranial haemorrhage (ICH) in patients treated with dabigatran etexilate (Pradaxa®) 110mg and 150mg bid compared to those treated with well-controlled warfarin.1 As part of the primary safety endpoint, the analysis evaluated 154 intracranial haemorrhages that occurred in 153 patients during the trial, including bleeding sites, rates, risk factors, associated trauma, and outcomes. Results of this safety analysis were recently published online in Stroke: The Journal of the American Heart Association.

Back to news